CFM
ALDX icon

Catalyst Funds Management’s Aldeyra Therapeutics ALDX Stock Holding History

Catalyst Funds Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,100
Closed -$65.4K – 461
2024
Q4 		$65.4K Buy
13,100
+12,500
+2,083% +$64.1K 0.02% 277
2024
Q3 		$3.23K Buy
+600
New +$2.86K ﹤0.01% 1255
2024
Q2 		– Sell
-4,760
Closed -$15.6K – 1158
2024
Q1 		$15.6K Buy
+4,760
New +$15.7K ﹤0.01% 815

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Catalyst Funds Management's ALDX Position: Q1 2025 in Review

Catalyst Funds Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2025, closing a stake of 13,100 shares — an estimated $65.4K sold.

Catalyst Funds Management first reported a position in ALDX in Q1 2024 and held it in 3 quarters. The position peaked at $65.4K in Q4 2024. 125 funds tracked by Wall St. Rank hold ALDX as of Q1 2025.

  • Catalyst Funds Management reported no remaining Aldeyra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 13,100 Aldeyra Therapeutics shares in Q1 2025, an estimated $65.4K.
  • Catalyst Funds Management first reported a position in Aldeyra Therapeutics in Q1 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Aldeyra Therapeutics position peaked at $65.4K in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2025.

Based on Catalyst Funds Management's 13F filing for Q1 2025, filed 14 May 2025.